Novaliq GmbH researches the use of semifluorinated alkanes manufactured by Fluoron GmbH in other medical disciplines. This subsidiary was founded in 2004 as a separate business with the aim of developing and marketing life-saving drug carrier systems for the treatment of serious respiratory diseases such as acute respiratory distress syndrome.

Semifluorinated alkanes (SFAs) that are already in use may also be developed for use as carrier fluids for the transportation of drugs. SFAs are able to transport active ingredients directly to the lungs where they enter the bloodstream and allow for the efficient treatment of various diseases. SFAs are also suitable for the manufacture of oxygen-rich and long-term stable oxygen substitutes, gas-permeable gels for wound coverage and organ conservation media.

The future means innovation: we have already acquired additional capital to sponsor clinical trials and to advance developments with the aim of relieving people's suffering around the world.

You can find more information at www.novaliq.de.